← Search & browse all drugs
VARIOUS › DIAGNOSTIC RADIOPHARMACEUTICALS › CENTRAL NERVOUS SYSTEM › Other central nervous system diagnostic radiopharmaceuticals
indium (111In) pentetic acid
V09AX01
Forms & Strengths
- Vial for intravenous injection, 1 mL sterile solution
- Activity typically 3.7–37 MBq (0.1–1 mCi) per dose
- Formulated with DTPA as chelator
Adult Dosing
- Renal scintigraphy: 37–74 MBq (1–2 mCi) IV bolus
- Cerebrospinal‑fluid cisternography: 74–111 MBq (2–3 mCi) IV
- Infection/inflammation imaging: 111–185 MBq (3–5 mCi) IV
Pediatric Dosing
- Renal imaging: 0.1 mCi/kg (3.7 MBq/kg) up to 74 MBq (2 mCi)
- Cisternography: 0.2 mCi/kg (7.4 MBq/kg) up to 111 MBq (3 mCi)
- Infection imaging: 0.2–0.3 mCi/kg (7.4–11 MBq/kg)
Indications
- Renal tubular function and glomerular filtration imaging
- Cerebrospinal‑fluid leak detection (cisternography)
- Localization of infection/inflammation (e.g., osteomyelitis, abscess)
- Detection of certain tumors (e.g., neuroblastoma)
Mechanism of Action
- Indium‑111 emits gamma photons (171 keV, 245 keV) detected by gamma camera
- DTPA chelate remains extracellular, is filtered by glomeruli, and distributes in extracellular fluid
- Provides functional imaging of renal excretion, CSF pathways, and sites of inflammation
Contraindications
- Pregnancy unless diagnostic benefit outweighs fetal radiation risk
- Breast‑feeding (radiation to infant)
- Known hypersensitivity to indium‑111 DTPA or DTPA derivatives
Adverse Reactions
- Mild injection‑site pain or erythema
- Transient nausea, flushing, or headache
- Rare allergic reaction or anaphylaxis
- Radiation exposure‑related stochastic risk
Drug Interactions
- Concurrent renal‑altering drugs (e.g., diuretics, ACE inhibitors) may modify image interpretation
- Chelating agents (e.g., high‑dose DTPA therapy) can reduce indium binding
- Other radiopharmaceuticals administered within 24 h may cause image overlap
Curated Content: Needs Vetting Before Put to Clinical Use